brand_name_lc,generic_name,active_ingredients,drug_a,drug_b,severity,side_effects,mechanism,clinical_action,confidence,created_at
atorvastatin calcium 20mg,Atorvastatin Calcium,Atorvastatin,atorvastatin calcium 20mg,aspirin 300mg tablet,Minor,"Increased risk of bleeding, especially gastrointestinal bleeding.",Both drugs can inhibit platelet aggregation. Atorvastatin has been shown to increase the risk of bleeding events in patients taking aspirin.,Monitor for signs of bleeding. Consider dose adjustment if necessary.,1,2026-05-06
atorvastatin calcium 20mg,Atorvastatin Calcium,Atorvastatin,atorvastatin calcium 20mg,warfarin,Moderate,Increased risk of bleeding. Potentially altered INR.,Atorvastatin can increase the anticoagulant effect of warfarin.,"Monitor INR closely when initiating or discontinuing atorvastatin, or changing the dose. Adjust warfarin dose as needed.",1,2026-05-06
atorvastatin calcium 20mg,Atorvastatin Calcium,Atorvastatin,atorvastatin calcium 20mg,clopidogrel,Minor,Increased risk of bleeding.,Both drugs are antiplatelet agents. Concomitant use may increase the risk of bleeding.,Monitor for signs of bleeding. Use with caution.,1,2026-05-06
atorvastatin calcium 20mg,Atorvastatin Calcium,Atorvastatin,atorvastatin calcium 20mg,erythromycin,Moderate,Increased risk of myopathy and rhabdomyolysis.,"Erythromycin is a CYP3A4 inhibitor, which can increase the plasma concentrations of atorvastatin.","Avoid concomitant use. If unavoidable, use with extreme caution and consider a lower dose of atorvastatin.",1,2026-05-06
atorvastatin calcium 20mg,Atorvastatin Calcium,Atorvastatin,atorvastatin calcium 20mg,itraconazole,Moderate,Increased risk of myopathy and rhabdomyolysis.,"Itraconazole is a potent CYP3A4 inhibitor, which can increase the plasma concentrations of atorvastatin.","Avoid concomitant use. If unavoidable, use with extreme caution and consider a lower dose of atorvastatin.",1,2026-05-06
atorvastatin calcium 20mg,Atorvastatin Calcium,Atorvastatin,atorvastatin calcium 20mg,cyclosporine,Major,Increased risk of myopathy and rhabdomyolysis. Potential for increased cyclosporine levels.,"Cyclosporine is a CYP3A4 inhibitor and P-glycoprotein inhibitor, which can significantly increase the plasma concentrations of atorvastatin. Atorvastatin may also increase cyclosporine levels.","Avoid concomitant use. If unavoidable, use with extreme caution and a significantly reduced dose of atorvastatin. Monitor for signs of myopathy and rhabdomyolysis. Monitor cyclosporine levels.",1,2026-05-06
atorvastatin calcium 20mg,Atorvastatin Calcium,Atorvastatin,atorvastatin calcium 20mg,gemfibrozil,Major,Increased risk of myopathy and rhabdomyolysis.,Both drugs can cause myopathy. Gemfibrozil increases the risk of myopathy when used with statins.,"Avoid concomitant use. If unavoidable, use with extreme caution and monitor closely for muscle pain, tenderness, or weakness.",1,2026-05-06
atorvastatin calcium 20mg,Atorvastatin Calcium,Atorvastatin,atorvastatin calcium 20mg,niacin (lipid-lowering doses),Moderate,Increased risk of myopathy and rhabdomyolysis.,Both drugs can cause myopathy. Concomitant use increases the risk.,Use with caution and monitor for signs of myopathy. Consider a lower dose of atorvastatin.,1,2026-05-06
atorvastatin calcium 20mg,Atorvastatin Calcium,Atorvastatin,atorvastatin calcium 20mg,amiodarone,Moderate,Increased risk of myopathy and rhabdomyolysis.,"Amiodarone may inhibit CYP3A4, potentially increasing atorvastatin levels. Both can contribute to myopathy.",Use with caution and monitor for signs of myopathy. Consider a lower dose of atorvastatin.,1,2026-05-06
atorvastatin calcium 20mg,Atorvastatin Calcium,Atorvastatin,atorvastatin calcium 20mg,verapamil,Minor,Potential for increased atorvastatin levels and myopathy.,"Verapamil may inhibit CYP3A4, leading to increased atorvastatin concentrations.",Use with caution and monitor for signs of myopathy. Consider a lower dose of atorvastatin.,1,2026-05-06
atorvastatin calcium 20mg,Atorvastatin Calcium,Atorvastatin,atorvastatin calcium 20mg,telithromycin,Moderate,Increased risk of myopathy and rhabdomyolysis.,"Telithromycin is a potent CYP3A4 inhibitor, which can increase the plasma concentrations of atorvastatin.","Avoid concomitant use. If unavoidable, use with extreme caution and consider a lower dose of atorvastatin.",1,2026-05-06
atorvastatin calcium 20mg,Atorvastatin Calcium,Atorvastatin,atorvastatin calcium 20mg,diltiazem,Minor,Potential for increased atorvastatin levels and myopathy.,"Diltiazem may inhibit CYP3A4, leading to increased atorvastatin concentrations.",Use with caution and monitor for signs of myopathy. Consider a lower dose of atorvastatin.,1,2026-05-06
atorvastatin calcium 20mg,Atorvastatin Calcium,Atorvastatin,atorvastatin calcium 20mg,ritonavir,Moderate,Increased risk of myopathy and rhabdomyolysis.,"Ritonavir is a potent CYP3A4 inhibitor, which can significantly increase the plasma concentrations of atorvastatin.","Avoid concomitant use. If unavoidable, use with extreme caution and consider a lower dose of atorvastatin.",1,2026-05-06
atorvastatin calcium 20mg,Atorvastatin Calcium,Atorvastatin,atorvastatin calcium 20mg,clarithromycin,Moderate,Increased risk of myopathy and rhabdomyolysis.,"Clarithromycin is a CYP3A4 inhibitor, which can increase the plasma concentrations of atorvastatin.","Avoid concomitant use. If unavoidable, use with extreme caution and consider a lower dose of atorvastatin.",1,2026-05-06
atorvastatin calcium 20mg,Atorvastatin Calcium,Atorvastatin,atorvastatin calcium 20mg,digoxin,Minor,Potential for increased digoxin levels.,Atorvastatin may increase digoxin levels.,"Monitor digoxin levels, especially when initiating or discontinuing atorvastatin, or changing the dose. Adjust digoxin dose as needed.",1,2026-05-06
synjardy 12.5,Empagliflozin + Metformin,Empagliflozin|Metformin,synjardy 12.5,aspirin 300mg tablet,Minor,Increased risk of gastrointestinal bleeding.,"Aspirin can irritate the gastric mucosa, and SGLT2 inhibitors like empagliflozin may have a mild diuretic effect which could potentially exacerbate this.",Monitor for signs of gastrointestinal bleeding. Consider gastroprotective measures if indicated.,1,2026-05-06
synjardy 12.5,Empagliflozin + Metformin,Empagliflozin|Metformin,synjardy 12.5,aspirin,Minor,Increased risk of gastrointestinal bleeding.,"Aspirin can irritate the gastric mucosa, and SGLT2 inhibitors like empagliflozin may have a mild diuretic effect which could potentially exacerbate this.",Monitor for signs of gastrointestinal bleeding. Consider gastroprotective measures if indicated.,1,2026-05-06
ozempic 1mg,semaglutide,semaglutide,ozempic 1mg,metformin,Moderate,"Increased risk of hypoglycemia (low blood sugar), gastrointestinal disturbances (nausea, vomiting, diarrhea, constipation).","Semaglutide enhances glucose-dependent insulin secretion and suppresses glucagon secretion. When combined with metformin, which also lowers blood glucose, the risk of hypoglycemia is increased. Both can cause gastrointestinal side effects.",Monitor blood glucose levels closely. Adjust dosage of either or both medications if hypoglycemia occurs. Advise patient on symptoms of hypoglycemia and how to manage it. Counsel on potential for increased GI side effects.,1,2026-05-06
ozempic 1mg,semaglutide,semaglutide,ozempic 1mg,insulin,Major,"Significant increased risk of hypoglycemia. Symptoms include dizziness, confusion, sweating, tremor, palpitations, and in severe cases, seizures and coma.","Both semaglutide and insulin lower blood glucose levels. Their combined effect can lead to additive glucose-lowering effects, significantly increasing the risk of severe hypoglycemia.","Avoid concomitant use if possible. If use is necessary, reduce insulin dose significantly (e.g., by 20-50% or as guided by clinical judgment) and monitor blood glucose very closely. Educate patient thoroughly on recognizing and managing hypoglycemia. Consider frequent self-monitoring of blood glucose.",1,2026-05-06
ozempic 1mg,semaglutide,semaglutide,ozempic 1mg,warfarin,Minor,"Potential for altered INR (International Normalized Ratio), leading to increased risk of bleeding or clotting.","GLP-1 receptor agonists like semaglutide may affect the pharmacokinetics of warfarin, potentially by altering cytochrome P450 enzyme activity. This can lead to fluctuations in warfarin levels.","Monitor INR closely when initiating, discontinuing, or changing the dose of Ozempic in patients taking warfarin. Advise patient to report any signs of bleeding or bruising.",1,2026-05-06
ozempic 1mg,semaglutide,semaglutide,ozempic 1mg,omeprazole,Minor,"No significant clinical impact expected, but individual GI responses can vary.","Theoretical interaction due to potential impact on gastric emptying, but generally not clinically significant.",Monitor for any unusual gastrointestinal symptoms. No specific action typically required.,1,2026-05-06
ozempic 1mg,semaglutide,semaglutide,ozempic 1mg,pantoprazole,Minor,"No significant clinical impact expected, but individual GI responses can vary.","Theoretical interaction due to potential impact on gastric emptying, but generally not clinically significant.",Monitor for any unusual gastrointestinal symptoms. No specific action typically required.,1,2026-05-06
sporlac,Probiotic,Probiotic,sporlac,,,,,,0.9,2026-05-13
clindac-a,Clindamycin Phosphate,Clindamycin Phosphate,clindac-a,alprax plus tablet sr,Minor,Increased risk of gastrointestinal side effects.,"Clindamycin can cause GI upset. Although topical, systemic absorption, though minimal, could theoretically exacerbate GI issues in combination with alprazolam (which can also cause GI side effects).",Monitor for gastrointestinal symptoms. No specific action usually required.,0.9,2026-05-13
clindac-a,Clindamycin Phosphate,Clindamycin Phosphate,clindac-a,corex dx syrup,Minor,Potential for increased drowsiness or dizziness. Monitor for respiratory depression if systemic absorption of clindamycin occurs significantly.,"Clindamycin, especially with significant systemic absorption, can cause CNS effects. Codeine in Corex DX is a CNS depressant and can cause drowsiness. The combination might potentiate these effects. Dextromethorphan can also have CNS effects.",Advise patient to avoid activities requiring mental alertness. Monitor for excessive sedation.,0.9,2026-05-13
clindac-a,Clindamycin Phosphate,Clindamycin Phosphate,clindac-a,erythromycin,Moderate,Decreased efficacy of clindamycin.,"Erythromycin is a 23S ribosomal subunit inhibitor, similar to clindamycin, and can antagonistically bind to the bacterial ribosome, reducing the effectiveness of clindamycin.","Avoid co-administration. If combination is necessary, monitor for treatment failure.",0.9,2026-05-13
clindac-a,Clindamycin Phosphate,Clindamycin Phosphate,clindac-a,metronidazole,Minor,Increased risk of gastrointestinal side effects.,"Both clindamycin and metronidazole can cause gastrointestinal upset, including nausea, vomiting, and diarrhea. Concurrent use may increase the likelihood or severity of these effects.",Monitor for gastrointestinal symptoms. Advise patient on dietary measures to reduce GI upset.,0.9,2026-05-13
kojiclar-h,Kojic acid + Hydroquinone,Kojic acid|Hydroquinone,kojiclar-h,,,,,,0.8,2026-05-13